==============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-9601
Date of Report (date of earliest event reported): December 17, 2008
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
DELAWARE 43-0618919
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2503 SOUTH HANLEY ROAD
ST. LOUIS, MISSOURI 63144
(Address of principal executive offices) (Zip Code)
(314) 645-6600
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
/ / Written communications pursuant to Rule 425 under the Securities Act.
/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
/ / Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act.
/ / Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act.
==============================================================================
ITEM 8.01 OTHER EVENTS.
On December 17, 2008, K-V Pharmaceutical Company (the "Company")
announced in a press release that its Ther-Rx Corporation branded
pharmaceutical subsidiary has enhanced the formulation of one of its leading
products, PrimaCare ONE(R).
A copy of the press release is attached hereto as Exhibit 99. The
information in this Item 8.01, including the exhibit, shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) The following exhibit is furnished as part of this report:
Exhibit Number Description
-------------- -----------
99 Press Release dated December 17, 2008, issued
by K-V Pharmaceutical Company.
The Company has posted this Form 8-K on its Internet website at
www.kvpharmaceutical.com.
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: December 19, 2008
K-V PHARMACEUTICAL COMPANY
By: /s/ Richard H. Chibnall
---------------------------------
Richard H. Chibnall
Vice President, Finance